Skip to content

FET-PET/MRI Based Treatment Planning for Glioblastoma Multiforme in Post-Surgical Patients (FET-TREAT)

Glioblastoma Multiforme

Glioblastoma multiforme (GBM) represent the most common primary brain malignancy and prognosis remains poor. The most common subtype is glioblastoma which has a 5-year survival rate of approximately 5%. Despite advances in MRI techniques, accurately determining total extent of tumor remains a challenge. The result is incomplete treatment resulting in reduced survival or overtreatment resulting in avoidable treatment related morbidity. A more accurate means of assessing tumor extent is needed to guide management to improve patient survival and quality of life.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

Each participant must meet all of the following inclusion criteria to participate in this study:

* ≥ 18 years of age
* Diagnosis of glioblastoma multiforme
* Post-maximally safe surgical resection
* No prior radiation or systemic treatment for high grade glioma
* Able to tolerate PET/MRI scan with intravenous contrast
* Willing to provide informed consent

Exclusion Criteria:

All participants meeting any of the following exclusion criteria at baseline screening will be excluded from participation in this study:

* MRI contraindication
* Creatinine clearance \< 30mL/min
* Inability to lie still for 60 minutes
* Gadolinium allergy
* Positive pregnancy test
* Breastfeeding
* Patient unable to follow the protocol for any reason

Study Location

Sunnybrook Health Sciences Centre
Sunnybrook Health Sciences Centre
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Amit Singnurkar, MD

[email protected]
416-48-6100
Study Sponsored By
Sunnybrook Health Sciences Centre
Participants Required
More Information
Study ID: NCT06451042